GO:0042281 dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferase activity

Dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferase activity (GO:0042281) is a molecular function that catalyzes the addition of the first glucose residue to the lipid-linked oligosaccharide precursor during N-linked glycosylation. This step is essential for the proper assembly of the Glc3Man9GlcNAc2-PP-Dol core oligosaccharide, which is subsequently transferred to nascent proteins in the endoplasmic reticulum. The enzyme responsible for this activity is ALG6, a member of the ALG (asparagine-linked glycosylation) family of glycosyltransferases. The importance of GO:0042281 is underscored by its link to congenital disorders of glycosylation (CDG). Mutations in ALG6 cause ALG6-CDG (also known as CDG-Ic), an autosomal recessive disorder characterized by a multi-allelic origin and a broad range of clinical symptoms. Patients may present with developmental delay, seizures, and other neurological impairments, and more recently, dilated cardiomyopathy has been reported in a patient with ALG6-CDG. These findings highlight the critical role of this enzymatic activity in human health and disease. For researchers, GO:0042281 represents a focal point for understanding the molecular basis of N-linked glycosylation and its associated pathologies. Investigating this activity involves a combination of genetic, biochemical, and cell biology approaches, including the use of CRISPR-engineered cell and animal models to dissect the functional consequences of ALG6 mutations. This article provides a comprehensive overview of the definition, mechanism, key genes, disease relevance, and research methods associated with GO:0042281.

GO:0042281 is defined as the catalysis of the addition of the first glucose residue to the lipid-linked oligosaccharide precursor for N-linked glycosylation. Specifically, it describes the transfer of glucose from dolichyl phosphate glucose (Dol-P-Glc) onto the lipid-linked oligosaccharide Man9GlcNAc2-PP-Dol, forming Glc1Man9GlcNAc2-PP-Dol. This activity is synonymous with dolichyl-P-Glc:Man9GlcNAc2-PP-dolichyl glucosyltransferase activity and is a key step in the biosynthesis of the N-glycan precursor.

GO:0042281 is essential for the proper assembly of the N-linked glycosylation precursor, a process that affects the folding, stability, and function of a vast array of secretory and membrane proteins. Disruption of this activity leads to ALG6-CDG, a multi-allelic disorder with significant clinical heterogeneity, ranging from neurological impairment to cardiac involvement such as dilated cardiomyopathy. Understanding this enzymatic step provides insights into the molecular mechanisms of glycosylation disorders and may inform therapeutic strategies.

The following genes are directly or indirectly involved in the N-linked glycosylation pathway that includes GO:0042281, with ALG6 being the primary enzyme responsible for this activity.

The activity of GO:0042281 is primarily regulated by the expression level and mutational status of the ALG6 gene. No specific allosteric or post-translational regulators have been definitively described in the provided literature. However, the overall N-linked glycosylation pathway is subject to metabolic regulation, and defects in ALG6 lead to disease, indicating that its activity is tightly controlled.

Mutations in ALG6 cause congenital disorder of glycosylation type Ic (ALG6-CDG), an autosomal recessive condition with a multi-allelic origin. Patients typically present with developmental delay, seizures, hypotonia, and other neurological symptoms. The clinical severity can vary, and some patients may have additional complications.

A novel mutation in ALG6 has been reported in a patient with ALG6-CDG who also developed dilated cardiomyopathy. This case report expands the phenotypic spectrum of ALG6-CDG to include cardiac involvement, suggesting that GO:0042281 deficiency can affect multiple organ systems.

The activity of GO:0042281 can be measured in vitro using microsomal fractions from cells or tissues, with radiolabeled Dol-P-[14C]Glc as the donor and Man9GlcNAc2-PP-Dol as the acceptor. The product Glc1Man9GlcNAc2-PP-Dol is then analyzed by thin-layer chromatography or high-performance liquid chromatography. These assays are essential for confirming the functional impact of ALG6 mutations.

Mass spectrometry-based glycomics and glycoproteomics can profile the N-glycan structures on proteins from cells with altered ALG6 activity. This approach reveals the accumulation of Man9GlcNAc2 or other truncated glycans, providing a fingerprint of defective glucosylation. It is useful for diagnosing ALG6-CDG and assessing the efficacy of potential therapies.

CRISPR-Cas9 technology enables the generation of ALG6 knockout, point mutant, and knock-in cell lines to study GO:0042281. These models allow researchers to dissect the precise role of ALG6 in glycosylation and disease. For example, knockout of ALG6 in HEK293 cells leads to the accumulation of Man9GlcNAc2-PP-Dol, confirming the enzymatic block.

RNA sequencing and quantitative proteomics can reveal global changes in gene expression and protein abundance upon ALG6 perturbation. These methods help identify compensatory pathways and downstream effectors of glycosylation stress. They are particularly useful for understanding the multi-systemic effects of ALG6-CDG.

Researchers studying dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in glycosylation pathways or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and library screening.

GO:0042281, dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferase activity, is a fundamental enzymatic step in N-linked glycosylation catalyzed by ALG6. Its dysfunction leads to ALG6-CDG, a multi-allelic disorder with diverse clinical manifestations including dilated cardiomyopathy. Understanding this activity through biochemical, genetic, and CRISPR-based models is crucial for elucidating disease mechanisms and developing potential therapies.